Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2012; 33(02): 89-94
DOI: 10.4103/0971-5851.99737
REVIEW ARTICLE

mTOR inhibition in management of advanced breast cancer

Shona Nag
Department of Medical Oncology, Jehangir Hospital and Medical Centre, Pune, Maharashtra, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

The mTOR pathway is becoming increasingly important in several cancers including breast cancer. This review will focus on the role of its inhibition in the management of advanced breast cancer.

Keywords

Apoptosis - everolimus - hormone


Publication History

Article published online:
13 April 2022

© 2012. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-6.
  • 2 Available from: http://www.cancer.gov/cancertopics/druginfo/fda-temsirolimus. [Last Accessed on 2011 Apr 7]
  • 3 Yamnik RL, Holz MK. mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett 2010;584:124-8.
  • 4 Everolimus in combination with trastuzumab and paclitaxel in the treatment of her2 positive locally advanced or metastatic breast cancer (BOLERO-1). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00876395?term=bolero-1 and rank=1. [Last Accessed on 2011 Nov]
  • 5 Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010;116:4256-65.
  • 6 Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: Development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45.
  • 7 Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
  • 8 Burstein HJ. Novel agents and future directions for refractory breast cancer. Semin Oncol 2011;38 Suppl 2:S17-24.
  • 9 Johnston SR. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 2006;12:1061s-1068s.
  • 10 Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331S-6S.
  • 11 Hortobagyi GN. Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. 2011 San Antonio Breast Cancer Symposium (SABCS Updated late breaking abstract No. S3-7. December 7, 2011).
  • 12 Gnant M, Beermann B. 8 th European Breast Cancer Conference (EBCC-8), Vienna, March 21-24, 2012. Breast Care (Basel) 2012;7:170-6.
  • 13 Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60.
  • 14 Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 2012;30:2718-24.
  • 15 Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7.
  • 16 Bachelot T, Bourgier C, Cropet C, et al. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Presented at the 33 rd Annual San Antonio Breast Cancer Symposium. San Antonio, Texas: 2010. Dec 8-12.
  • 17 Mayer IA, Means-Powell J, Abramson VG, et al. Phase II trial of RAD001 (everolimus), an mTOR inhibitor with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Program and abstracts of the 34 th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas: 2011. December 6-10. Abstract PD09-06.).
  • 18 Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des 2012;18:2766-77.
  • 19 Al-Batran SE, Ducreux M, Ohtsu A. mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer 2012;130:491-6.
  • 20 Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk Lymphoma 2009;50:1916-30.
  • 21 Frenette C, Gish R. Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J Gastroenterol 2012;18:498-506.
  • 22 Available from: http://www.genengnews.com/gen-news-highlights/novartis-afinitor-cleared-by-fda-for-treating-sega-tumors-in-tuberous-sclerosis/81244159/. [Last Accessed on 2012 Mar 16].
  • 23 Available from: http://www.genengnews.com/gen-news-highlights/positive-trial-data-leads-novartis-to-plan-breast-cancer-filing-for-afinitor-by-year-end/81245384/. [Last Accessed on 2012 Mar 16].
  • 24 Daily everolimus in combination with trastuzumab and vinorelbine in her2/neu positive women with locally advanced or metastatic breast cancer (BOLERO-3). Available from: http://clinicaltrials.gov/ct2/show/NCT01007942?term=BOLERO-3&rank=1. [Last Accessed on 2011 Nov].
  • 25 Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, et al. Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway. J Clin Oncol 2012.
  • 26 World Cancer Report. International agency for research on cancer. Available from: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900. [Last Accessed on 2011 Dec].